Abstract: The present disclosure relates to a boron compound useful in an organic light-emitting diode and an organic light-emitting diode comprising same and, more particularly, to a boron compound represented by any one of [Chemical Formula A], wherein [Chemical Formula A] is as defined in the description.

Abstract: An embodiment solid electrolyte includes a first compound and a second compound. The first compound is represented by a first chemical formula Li7-aPS6-a(X11-bX2b)a, wherein X1 and X2 are the same or different and each represents F, Cl, Br, or I, and wherein 0<a?2 and 0<b<1, and the second compound is represented by a second chemical formula Li7-cP1-2dMdS6-c-3d(X11-eX2e)c, wherein X1 and X2 are the same or different and each represents F, Cl, Br, or I, wherein M represents Ge, Si, Sn, or any combination thereof, and wherein 0<c?2, 0<d<0.5, and 0<e<1.

Abstract: The present invention relates to a novel heterocyclic compound usable in an organic light-emitting device and to an organic light-emitting device comprising same, wherein [chemical formula A] is as described in the detailed description of the invention.

Abstract: Disclosed is a polycyclic aromatic compound that can be employed in an organic layer of an organic electroluminescent device. Also disclosed is a highly efficient organic electroluminescent device including the polycyclic aromatic compound. The use of the polycyclic aromatic compound significantly improves the luminous efficiency of the device.

Abstract: The present invention relates to: a composition for promoting the proliferation of pluripotent stem cells, containing, as an active ingredient, cP1P or a pharmaceutically acceptable salt thereof; and a composition added to a stem cell culture liquid. When culturing stem cells by using a composition for promoting the proliferation of stem cells and a composition added to a stem cell culture medium, according to the present invention, sternness can be strengthened, growth can be promoted, and apoptosis can be inhibited.

Abstract: A pharmaceutical or health food composition for preventing or treating Parkinson's disease containing O-cyclic phytosphingosine-1-phosphate. The composition can prevent the death of SH-SY5Y nerve cells, which are dopaminergic nerve cells, and increase the expression of tyrosine hydroxylase, an enzyme required for dopamine formation. Accordingly, the composition can be effectively used for preventing or treating Parkinson's disease.

Abstract: The present disclosure provides a pharmaceutical composition for preventing or treating sepsis or septic shock comprising P1P or a derivative thereof. The present composition improves the survival rate of mice with sepsis induced by LPS or CLP treatment, as well as reduces the secretion of cytokines. Further, it helps to enhance the proliferation and function of vascular endothelial cells and increases the expression of SIRT1 protein which decreases in a sepsis patient. Accordingly, it can be effectively used in the treatment of sepsis.

Abstract: Disclosed in the present invention are a use as an immune enhancer of phytosphingosine-1-phosphate (P1P), O-cyclic P1P (cP1P), N-acetylphytosphingosine-1-phosphate (NAPS-1-P), and pharmaceutically acceptable salts thereof, and a pharmaceutical composition or vaccine for treating dementia, comprising such substance on the basis of a neuronal cell death inhibitory effect. The substance according to the present invention exhibits an effect of enhancing Th2 immune response and inhibiting Th1 immune response and has an effect of protecting neurons as well, and thus can be useful as an immune enhancer to help the production of antibodies for the development of a dementia vaccine, as well as an agent for preventing or treating dementia.

Abstract: Disclosed in the present invention are a use as an immune enhancer of phytosphingosine-1-phosphate (P1P), O-cyclic P1P (cP1P), N-acetylphytosphingosine-1-phosphate (NAPS-1-P), and pharmaceutically acceptable salts thereof, and a pharmaceutical composition or vaccine for treating dementia, comprising such substance on the basis of a neuronal cell death inhibitory effect. The substance according to the present invention exhibits an effect of enhancing Th2 immune response and inhibiting Th1 immune response and has an effect of protecting neurons as well, and thus can be useful as an immune enhancer to help the production of antibodies for the development of a dementia vaccine, as well as an agent for preventing or treating dementia.

Abstract: The present application relates to a composition for promoting proliferation of adult stem cells further comprising phytosphingosine-1-phosphate (P1P), O-cyclic P1P (cP1P), N-acetylphytosphingosine-1-phosphate (NAPS-1-P), and a pharmaceutically acceptable salt thereof in a basal medium, a composition for culturing adult stem cells comprising the same, or a composition for a serum-free or low-serum culture medium of adult stem cells. When the stem cells are cultured using the composition of the present application, the proliferation promotion, activity and differentiation capacity of the stem cells can be improved, and the death of the stem cells against external stress can be prevented.

Abstract: The present invention provides: O-cyclic phytospingosine-1-phosphate (O-C-P1P), N-cyclic phytospingosine-1-phosphate (N-C-P1P), a pharmaceutically acceptable salt thereof, or a solvate thereof; a preparation method therefor; a cosmetic composition comprising the same for preventing hair loss or for growing hair; and a pharmaceutical composition for preventing and treating hair loss or for growing hair.

Abstract: The present invention provides: O-cyclic phytospingosine-1-phosphate (0-C-P1P), N-cyclic phytospingosine-1-phosphate (N-C-P1P), a pharmaceutically acceptable salt thereof, or a solvate thereof; a preparation method therefor; a cosmetic composition comprising the same for preventing hair loss or for growing hair; and a pharmaceutical composition for preventing and treating hair loss or for growing hair.

Abstract: Disclosed is a composition for prevention and treatment of alopecia or for hair growth, comprising a phytosphingosine-1-phosphate derivative or a pharmaceutically acceptable salt thereof as an active ingredient. Also, a medicine comprising the composition and a quasi-drug comprising the composition are provided.

Abstract: Disclosed is a composition for prevention and treatment of alopecia or for hair growth, comprising a phytosphingosine-1-phosphate derivative or a pharmaceutically acceptable salt thereof as an active ingredient. Also, a medicine comprising the composition and a quasi-drug comprising the composition are provided.

Abstract: The present invention relates to liposomes comprising novel peptide antigens which play a role in regulating human immunity against hepatitis B virus, more specifically, to peptide groups corresponding to epitopes of antigens derived from X protein of HBV which induce cycotoxic T lymphocytes against the virus or immunological tolerance to the virus, and pH-sensitive liposomes comprising said peptide groups to induce cellular immunity so that CTLs specific to the virus can be produced. Since peptide antigens derived from X protein such as X3, X4, X5, X6 and X7 activate CTL which can recognize HBV antigens present in human body, and can also be recognized by the CTL, the said liposomes can be used for the development of proposed therapeutic agents for the prevention and treatment of HBV-associated diseases.

Abstract: The present invention relates to liposomes comprising novel peptide antigens which play a role in regulating human immunity against hepatitis B virus, more specifically, to peptide groups corresponding to epitopes of antigens derived from X protein of HBV which induce cytotoxic T lymphocytes against the virus or immunological tolerance to the virus, and pH-sensitive liposomes comprising said peptide groups to induce cellular immunity so that CTLs specific to the virus can be produced. Since peptide antigens derived from X protein such as X3, X4, X5, X6 and X7 activate CTL which can recognize HBV antigens present in human body, and can also be recognized by the CTL, the liposomes can be used for the development of proposed therapeutic agents for the prevention and treatment of HBV-associated diseases.